Skip to main content

Rheuma Tolerance for Cure

Objective

In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progression by inhibiting maturation/expansion of pathogenic autoimmune responses through immune tolerising treatments of subjects not only in early
stages of joint inflammation (undifferentiated arthritis and early RA) but also in even earlier defined stages i.e. before onset of joint inflammation, when patients have arthralgia and/or bone loss, or sub-clinical stages of joint inflammation.

Today, no drugs are approved for these early phases of RA development, where symptoms such as pain and fatigue cause major loss of life quality and where successful interference would prevent onset of disease. Thus, an important part of our work will be to achieve a better understanding of this as yet unexplored phase of disease. In the proposed project we will develop and validate new methods to identify individuals at high risk for RA, tools to monitor disease progress and expand and further develop cohorts suitable for these purposes.
Furthermore we will validate and standardise methods to monitor immune tolerance to be used in clinical trials for tolerising therapies for RA.
The aim is thus to interfere with the specific immune reactions that contribute to RA symptoms in such a way that a specific and long-lasting therapeutic effect (ultimately a cure) is accomplished for a major proportion of RA patients and prevention of diseases is accomplished in individuals at high risk for RA.

Investigator-initiated as well as company-sponsored clinical trials in well stratified patient groups will be performed in collaboration with SMEs and/or contributing pharma companies and their immune effects studied using the same panel of biomarkers allowing for standardisation across protocols. Our ambition is also to disseminate our experiences from RA to other rheumatic and other immune-mediated diseases.

Call for proposal

H2020-JTI-IMI2-2016-09-two-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

KAROLINSKA INSTITUTET
Address
Nobels Vag 5
17177 Stockholm
Sweden
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 190 000

Participants (19)

Deutsches Rheuma-Forschungszentrum Berlin
Germany
EU contribution
€ 465 000
Address
Chariteplatz 1
10117 Berlin
Activity type
Research Organisations
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 465 000
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
KING'S COLLEGE LONDON
United Kingdom
EU contribution
€ 465 000
Address
Strand
WC2R 2LS London
Activity type
Higher or Secondary Education Establishments
THE UNIVERSITY OF BIRMINGHAM
United Kingdom
EU contribution
€ 465 000
Address
Edgbaston
B15 2TT Birmingham
Activity type
Higher or Secondary Education Establishments
UNIVERSITATSKLINIKUM ERLANGEN
Germany
EU contribution
€ 465 000
Address
Maximiliansplatz 2
91054 Erlangen
Activity type
Higher or Secondary Education Establishments
UNIVERSITY OF NEWCASTLE UPON TYNE
United Kingdom
EU contribution
€ 465 000
Address
Kings Gate
NE1 7RU Newcastle Upon Tyne
Activity type
Higher or Secondary Education Establishments
UNIVERSITY OF GLASGOW
United Kingdom
EU contribution
€ 465 000
Address
University Avenue
G12 8QQ Glasgow
Activity type
Higher or Secondary Education Establishments
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 595 000
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
THE UNIVERSITY OF QUEENSLAND
Australia
EU contribution
€ 300 000
Address
St Lucia
4072 Brisbane
Activity type
Higher or Secondary Education Establishments
SEMMELWEIS EGYETEM
Hungary
EU contribution
€ 180 000
Address
Ulloi Utca 26
1085 Budapest
Activity type
Higher or Secondary Education Establishments
APITOPE INTERNATIONAL NV
Belgium
EU contribution
€ 240 000
Address
Agoralaan A Bis
3590 Diepenbeek
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ANOCCA AB
Sweden
EU contribution
€ 240 000
Address
Forskargatan 20C
151 36 Sodertalje
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FONDAZIONE PER L ISTITUTO DI RICERCA IN BIOMEDICINA
Switzerland
EU contribution
€ 0
Address
Via Vincenzo Vela 6
6500 Bellinzona
Activity type
Research Organisations
JANSSEN PHARMACEUTICA NV
Belgium
EU contribution
€ 0
Address
Turnhoutseweg 30
2340 Beerse
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UCB BIOPHARMA SRL
Belgium
EU contribution
€ 0
Address
Allee De La Recherche 60
1070 Bruxelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
United Kingdom
EU contribution
€ 0
Address
Great West Road 980
TW89GS Brentford
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SANOFI-AVENTIS DEUTSCHLAND GMBH
Germany
EU contribution
€ 0
Address
Bruningstrasse 50
65929 Frankfurt Am Main
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BRISTOL-MYERS SQUIBB COMPANY CORP
United States
EU contribution
€ 0
Address
Park Avenue 345
10154 New York
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PFIZER LIMITED
United Kingdom
EU contribution
€ 0
Address
Ramsgate Road
CT13 9NJ Sandwich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)